中文摘要：

目的 观察氨溴索雾化吸入联合顺尔宁对难治性哮喘的临床疗效.方法 将我院收治的难治性哮喘发作患者124例随机分为两组,每组62例,对照组予以长效β2受体激动剂联合大剂量的糖皮质激素（LABA）治疗,观察组在LABA治疗基础上加用顺尔宁联合氨溴索雾化吸入.结果 经过14 d治疗,观察组总有效率为90.3％,显著高于对照组的64.5％（P＜ 0.05）;治疗后观察组的FEV1、PFEV1、FVC、PFVC值依次为（3.17±0.54）L/s、（85.77±10.40）％、（3.97±0.80）L/s、（84.36±10.24）％,均显著高于对照组（P＜0.05）;临床症状也较对照组改善.结论 顺尔宁联合氨溴索雾化吸入治疗难治性哮喘的疗效确切,值得临床推广.

英文摘要：

Objective To observe the clinical efficacy of montelukast and ambroxol aerosol inhalation in treatment of refractory asthma. Methods One hundred and twenty-four cases patients of refractory asthma admitted were randomly divided into two groups in our hospital, each had 62 cases. The control group accepted the treatment of high dose of glucocorticoid combined with long-acting 132-agonists （LABA）. The observation group accepted the treatment of montelukast combined ambroxol inhalation based on LABA treatment. Results After 14 d treatment, the total effective rate of the observation group was 90.3%, significantly higher than the control group which was 64.5%（/9 〈 0.05）; After treatment, the FEV1, PFEV1, FVC, PFVC value of the observation group was （3.17±0.54） L/s, （85.77±10.40）%, （3.97±0.80） L/s, （84.36±10.24）%, which were all significantly higher than that in the control group（P 〈 0.05）, and the clinical symptoms were all improved compared with the control group. Conclusion It has a significant effect by montelukast combined am- broxol inhalation on the refractory asthma patients, it is worthy of promotion.